seen on
http://www.aastocks.com :
http://www.aastocks.com/en/news/hk6/257/now.465699.htmlFOSUN INTL (00656) cut to Underperform with target lowered to $4.2 by BofA ML(2011-12-12)
Bank of America Merrill Lynch reported on FOSUN INTL (00656) stating its Underperform rating and target $4.2 with the following details:
Downgrade from Buy to U/P; A relative call vs. peers
We downgrade Fosun International to U/P from Buy as
i) it has significant exposure (74% in terms of EBIT) to cyclical sectors including steel, mining and property which are expected to encounter headwinds in the near term and
ii) it is trading at a premium relative to peers, yet we expect lower ROE in 2012/ 13E will drive a de-rating of multiples.
As such, we believe it is likely to underperform relative to peers and hence, we downgrade the stock to U/P.
Substantial downside to consensusWe cut 2012-13E earnings by 23-43%, and expect Fosun 2H11 recurring earnings to decline by 37% vs. 1H11 largely on the back of weaker steel and iron ore prices. Our new 2012-13E earnings are 22% and 29%, respectively, below consensus.
Key catalysts to our call include worse-than-expected 2H11 results, weaker-than-expected monthly property sales for Forte and sustained weakness in steel and iron ore prices.
Key risks to our investment thesisWe think there are three key risks to our investment thesis:
i) It could outperform its peers on a potential macro turnaround given the cyclical nature of its business portfolio.
ii) Favorable corporate activities include successful listing of Hainan Mining and acquisitions of quality assets at favorable prices.
iii) Government policies such as easing of property restrictions and macro loosening initiatives.
Cutting PO to HK$4.20We lower our PO by 42% from HK$7.20 to HK$4.20 as:
1) we lower the value of listed investments based on market value by 19% to 28%,
2) we ascribe a sector average of 0.9x our 2012E P/B from 1.2x our 2012E P/B for Forte,
3) we cut the valuation of mining operations to reflect the latest iron-ore price forecast, and
4) we see higher net debt for the parent due to increased investments in landbank and pre-IPO investments.
5) Lower target discount to peers 47% avg from 38%. (r)
My personal notes -> FOSUN is perceived as a 100% cyclical and that is not trendy today. The justification of a lower PO through a "lower target discount to peers" is typical. It brings no real sense or justification.
Not a word about FOSUN Pharma. Why that ? No value at all here ?
Not a word about the retail branch. Why that ?
It is true that analysing those branches might be hard even for BoA-ML people. The company is very opaque and doesn't share a lot of information. Which in itself is very negative for me.
Yet, considering the past performance of this company, I view the current valuation as (perhaps excessively) cheap.
So my question is : when will be the time to rebuild a position on this company ? Any view to be shared ?